---
figid: PMC6721448__cancers-11-01197-g003
figlink: /pmc/articles/PMC6721448/figure/cancers-11-01197-f003/
number: F3
caption: BRAF-mediated signaling in normal and cancer cells. In normal cells, external
  growth stimuli activate receptor tyrosine kinase (RTK) and RAS, which relays growth
  signals to the mitogen-activated protein kinase (MAPK) pathway kinase cascade. In
  BRAF-driven cancers, mutant BRAF (BRAF *) can either act RAS independently as a
  monomer (Class 1) and as a dimer (Class 2) or act RAS dependently (Class 3) to hyperactivate
  cellular growth. Class 1 and Class 2 tumors respond to BRAF inhibitor-targeted therapy.
  However, various intrinsic or adaptive resistance mechanisms attenuate response
  to targeted BRAF inactivation. For example, preexisting NF1 loss, CDK4 mutations,
  and increased COT and YAP expression may specify intrinsic resistance. Therapy-induced
  HGF secretion and PI3K-AKT pathway activation are examples of some of the adaptive
  resistance mechanisms. On the other hand, EGFR-amplified population gives rise to
  acquired resistance to BRAF inhibitors.
pmcid: PMC6721448
papertitle: 'Targeting Oncogenic BRAF: Past, Present, and Future.'
reftext: Aubhishek Zaman, et al. Cancers (Basel). 2019 Aug;11(8):1197.
pmc_ranked_result_index: '16209'
pathway_score: 0.961235
filename: cancers-11-01197-g003.jpg
figtitle: BRAF-mediated signaling in normal and cancer cells
year: '2019'
organisms:
- Homo sapiens
ndex: 5fdeeae2-dedb-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6721448__cancers-11-01197-g003.html
  '@type': Dataset
  description: BRAF-mediated signaling in normal and cancer cells. In normal cells,
    external growth stimuli activate receptor tyrosine kinase (RTK) and RAS, which
    relays growth signals to the mitogen-activated protein kinase (MAPK) pathway kinase
    cascade. In BRAF-driven cancers, mutant BRAF (BRAF *) can either act RAS independently
    as a monomer (Class 1) and as a dimer (Class 2) or act RAS dependently (Class
    3) to hyperactivate cellular growth. Class 1 and Class 2 tumors respond to BRAF
    inhibitor-targeted therapy. However, various intrinsic or adaptive resistance
    mechanisms attenuate response to targeted BRAF inactivation. For example, preexisting
    NF1 loss, CDK4 mutations, and increased COT and YAP expression may specify intrinsic
    resistance. Therapy-induced HGF secretion and PI3K-AKT pathway activation are
    examples of some of the adaptive resistance mechanisms. On the other hand, EGFR-amplified
    population gives rise to acquired resistance to BRAF inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - MAPK1
  - AKT1
  - AKT3
  - PIK3R6
  - MAPK3
  - PIK3R4
  - PIK3CA
  - HGF
  - PIK3R5
  - CDK4
  - CROT
  - RAF1
  - NF1
  - AKT2
  - NRAS
  - MAP2K2
  - PIK3CB
  - PIK3CD
  - BRAF
  - MAP2K1
  - MTOR
  - KRAS
  - PIK3CG
  - PIK3R3
  - HRAS
  - Vemurafenib
  - Dabrafenib
  - tumors
genes:
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: HGF
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: CDK4
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: COT
  symbol: COT
  source: hgnc_alias_symbol
  hgnc_symbol: CROT
  entrez: '54677'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: 'NF1:'
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: PI3K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: (MTOR+
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
chemicals:
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Dabrafenib
  source: MESH
  identifier: C561627
diseases:
- word: tumors
  source: MESH
  identifier: D009369
figid_alias: PMC6721448__F3
redirect_from: /figures/PMC6721448__F3
figtype: Figure
---
